A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Recruiting now · Phase 4
Conditions studied: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
In brief
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Key facts
- Study ID
- NCT06876649
- Run by
- Eli Lilly and Company
- People needed
- 787
- Starts
- 2025-05-20
- Expected to finish
- 2032-12-01
- Last updated by the study team
- 2026-03-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
You may not qualify if…
- Exclusion criteria are defined in each ISA.
Where it is running
- Derriford Hospital — Plymouth, United Kingdom (enrolling)
- Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
- Florida Cancer Specialists — Sarasota, Florida, United States (enrolling)
- Tohoku University Hospital — Miyagi-Ken, Japan (enrolling)
- Hokkaido University Hospital — Sapporo, Japan (enrolling)
- Pratia MCM Krakow — Krakow, Poland (enrolling)
- Instytut Hermatologii I Transfuzjologii — Warsaw, Poland (enrolling)
- Seoul National University Hospital — Seoul, South Korea (enrolling)
- St James's University Hospital — Leeds, United Kingdom (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Mayo Clinic- Minnesota — Rochester, Minnesota, United States (enrolling)
- University Of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
- Cayuga Cancer Center — Ithaca, New York, United States (enrolling)
- Northwell Health — Lake Success, New York, United States (enrolling)
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York, United States (enrolling)
- Duke University Medical Center — Durham, North Carolina, United States (enrolling)
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (enrolling)
- University of Pennsylvania Hospital — Philadelphia, Pennsylvania, United States (enrolling)
- Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Swedish Cancer Institute — Seattle, Washington, United States (enrolling)
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
- Flinders Medical Centre — Adelaide, Australia (enrolling)
- Peter MacCallum Cancer Centre — Melbourne, Australia (enrolling)
- Linear Clinical Research — Victoria, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.